Gary Schieven Email & Phone Number

Princeton, Nj, Us

Hamilton, New Jersey, United States

Hamilton Township, New Jersey, United States

Lawrenceville, New Jersey

Biology lead for two immunology-oncology programs, leading to a STING agonist in Phase I and a second program on track for approval for entry into clinical development later in 2020. Utilized scRNAseq to identify mechanisms of action, and discovered that the BMS STING agonist spares human T cells from toxicity relative to competitors. Discovery Biology Lead for the TLR7/8 inhibitor program, resulting in 3 compounds approved for clinical development. The lead compound is entering Phase II studies later in 2020. Developed the clinical target engagement assay. Prepared relevant portions of IND filings and Investigator Brochure for the two drugs in the clinic. Supervised work at Biocon/Syngene (Bangalore, India) for my immunology-oncology and autoimmunity programs. Second Ondetti-Cushman award (highest BMS scientific award) in 2019 for this work.Core member of governance body for Discovery Fibrosis work. Led academic collaborations for immunology-oncology, fibrosis and autoimmune diseases. Led 3 additional full and early phase programs for autoimmune disease, including studies of regulatory T cells. Co-lead for Discovery Immunology Scleroderma strategy, including academic collaboration.

Lawrenceville, Nj

Discovery Biology lead for Lck kinase program full T cell inhibition, resulting in the discovery of extremely potent 10 - 30 picomolar kinase inhibitors that were highly efficacious in mouse collagen induced arthritis and solid organ transplant models. Discovered dasatinib (Spycel), one of the program compounds, was a highly potent BCR-Abl inhibitor. This work led to the nomination for development for CML for dasatinib, now approved for chronic myelogenous leukemia. Inventor on patent for use in Oncology. Discovered reasons dasatinib at clinical dose and schedule is not immunosuppressive.Biology lead for the p38 kinase program for rheumatoid arthritis and related autoimmune diseases, resulting in 3 First in Human and a successful Ph II trial in rheumatoid arthritis. Discovered the lead BMS p38 compound is a dual action kinase inhibitor, distinct from competitor compounds. Co-chair of the BMS Kinase/Phosphatase target class team. Received first Ondetti-Cushman award for work on kinases including dasatinib.Biology lead for the JAK3 program for autoimmune disease. Designed cellular assays including a high throughput flow cytometry assay of JAK-STAT signaling in human blood, leading to the BMS Leveraging Technology Award in 2012.

Greater Seattle Area

Initiated work as Lck program biology co-chair for Immunology, after transfer of program from Oncology. Developed processes for the first small molecule drug discovery program at the Seattle site, including purchase of automated liquid handlers used for both kinase and cellular assays. Researched oxidative stress induced immune cell signaling, leading to numerous publications and conference presentations. Extensive studies of tyrosine phosphorylation signal transduction pathways in T and B cells. Characterized tumor antigens for anti-solid tumor antibody programs.

Bs, Summa Cum Laude, Chemistry

Ph.D., Biochemistry

University of California Regents Fellowship

Postdoctoral Fellow

Fellow of the Leukemia Society of America with Prof. G. Steven Martin, Cellular and Molecular Biology, University of California.